SARS-COV-2 MPRO INHIBITOR COMPOUNDS

The disclosures herein relate to compounds of Formula (1′):or a salt thereof, wherein A, Q, X, Z, L, R2, R3 and R9 are defined herein, and their use in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro.

Saved in:
Bibliographic Details
Main Authors PICKWORTH, Mark, DE GRAAF, Chris, HIGUERUELO, Alicia Perez, CONGREVE, Miles Stuart, CHRISTOPHER, John Andrew, MASON, Jonathan Stephen, KULKARNI, Santosh S
Format Patent
LanguageEnglish
Published 14.03.2024
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The disclosures herein relate to compounds of Formula (1′):or a salt thereof, wherein A, Q, X, Z, L, R2, R3 and R9 are defined herein, and their use in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro.
Bibliography:Application Number: US202118258065